Vista Point Bio

Vista Point Bio is a strategic advisory firm that helps biotech and pharma leaders translate bold science into clear strategy, disciplined execution, and compelling narratives that drive alignment, investment, and progress. We support teams at critical inflection points — from early concept through clinical development, BD engagement, and investment readiness — with deep expertise in genetic medicines, first-in-class therapies targeting causal disease biology, and novel therapeutic platforms. With experience spanning rare and genetic diseases as well as cardiovascular, metabolic, CNS, and renal indications, we focus on breakthrough programs with the potential to reshape the future of medicine. Founded by Dr. Matt Killeen, a biotech executive and scientist with almost two decades of experience in translational research, R&D leadership, and portfolio strategy, Vista Point Bio delivers end-to-end perspectives across discovery, development, and commercialization — from early-stage platforms to clinical-stage assets. We provide strategic guidance in: - R&D and pipeline strategy - Program development and positioning - Opportunity assessments and scientific due diligence - Scientific narrative development to enable fundraising and partnerships Vista Point Bio also partners with investors to deliver rigorous, science-driven due diligence and opportunity assessments to support confident decision-making and long-term value creation. Vista Point Bio is the strategic advisory arm of Vista Point Therapeutic Innovations LLC. Email: matt@vistapointbio.com.